The impact of platinum-free interval on the efficacy of lenvatinib/pembrolizumab in advanced or recurrent endometrial cancer

Category Primary study
ConferenceEuropean Society For Medical Oncology Asia Congress, ESMO Asia 2025
Year 2025
This article has no abstract
Epistemonikos ID: 143ca37e9c9c97da907df7372076fbe145091ee0
First added on: Feb 28, 2026